New trial aims to boost survival in rare blood disease with stem cell transplant

NCT ID NCT06022939

Disease control Sponsor: SWOG Cancer Research Network Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding a stem cell transplant to standard chemotherapy helps people with newly diagnosed AL amyloidosis. About 338 participants will receive either chemo alone or chemo followed by a stem cell transplant. The goal is to see which approach better delays organ damage and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Daratumumab, cyclophosphamide, bortezomib, dexamethasone, melphalan, and autologous stem cell transplant
What this could lead to: If successful, this could show that adding a stem cell transplant to standard chemo helps people with AL amyloidosis live longer without major organ damage.
What could go wrong: This is a large phase 3 trial, but stem cell transplants carry serious risks like infection and organ damage. The added benefit over chemo alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 338 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Oct 2030

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * STEP 1: Participants must have systemic AL amyloidosis which is biopsy proven and includes histologically-confirmed by positive Congo red stain with green birefringence on polarized light microscopy, OR characteristic appearance by electron microscopy AND confirmatory AL amyloid typing (mass spectrometry-based proteomic analysis or immunofluorescence). If there is question regarding diagnosis, consult study chairs prior to registration * STEP 1: Participants must have measurable disease within 28 days prior to treatment if initiated prior to registration or within 28 days of registration as defined by at least one of the following: * Positive monoclonal serum immunofixation electrophoresis * Positive monoclonal urine immunofixation electrophoresis * Monoclonal plasma cells in bone marrow In addition, participants must also have a difference between the involved and uninvolved free light chain (dFLC) \>= 2 mg/dL * STEP 1: Participants may receive up to one cycle (or 28 days) of therapy prior to enrollment. If a patient receives \>= 75% of 1 cycle of protocol identical Dara-VCD, this will be considered 1 cycle of protocol induction. Any patient who receives less than 75% of 1 cycle of Dara-VCD or non-protocol therapy will still be eligible but will be treated per protocol. If protocol identical therapy is initiated prior to enrollment, this treatment is not continued but rather treatment is dictated per protocol * STEP 1: Participants may be receiving chronic corticosteroids if they are being given for disorders other than AL amyloidosis or myeloma * STEP 1: Participant must be \>= 18 years old * STEP 1: Participant must have Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0, 1, or 2 (PS = 3 may be allowed if secondary to neuropathy) * STEP 1: Participant must have a complete medical history and physical exam within 28 DAYS prior to registration * STEP 1: Participants must be willing to undergo high dose chemotherapy and autologous stem cell transplantation if they are randomized to the arm receiving high dose chemotherapy and autologous stem cell transplantation * STEP 1: Participants must be eligible to receive high dose chemotherapy with melphalan at a dose of 200 mg/m\^2 or 140 mg/m\^2 (200 mg/m\^2 is highly encouraged but not mandated). Transplant eligibility criteria are included in the general eligibility criteria listed below: * Participant must have a supine systolic blood pressure (BP) \>= 90 mmHg (at registration step-1, this may by supported by midodrine * Participant must have non-severe cardiac AL (meeting all the below criteria) as defined by: * N-terminal proB-type natriuretic peptide (NT proBNP) \< 5000 (if no NTproBNP, brain natriuretic peptide \[BNP\] must be available and \< 400) * Troponin T (TnT) \< 0.06. If not available, one of the following two criteria must be met: * High sensitivity troponin (hsTnT) T \< 75 or troponin I \< 0.1ng/dL * New York Heart Association (NYHA) I or II * Cardiac ejection fraction (EF) \>= 40% * STEP 1: Hemoglobin \>= 8.0 g/dL (\> 5 mmol/L); red blood cell transfusion allowed up to 7 day prior to registration (within 28 days prior to registration) (NOTE: Growth factor support granulocyte colony-stimulating factor \[G-CSF\] is permitted per institutional guidelines) * STEP 1: Leukocytes \>= 2 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 1: Absolute neutrophil count \>= 1.0 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 1: Platelets \>= 50 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 1: Total bilirubin =\< 1.5 times the institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to registration) * STEP 1: Direct bilirubin =\< 2.0 mg/dL (within 28 days prior to registration) * STEP 1: Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =\< 3x upper limit of normal (ULN) (except if secondary to hepatic involvement) (within 28 days prior to registration) * STEP 1: Alkaline phosphatase =\< 750 U/L (except if secondary to hepatic involvement) (within 28 days prior to registration) * STEP 1: Participants must have a serum creatinine =\< the institutional (I)ULN OR measured OR calculated creatinine clearance \>= 30 mL/min using the following Cockcroft-Gault formula. This specimen must have been drawn and processed within 28 days prior to registration * STEP 1: If peripheral neuropathy is present at diagnosis, participants must be grade 2 (moderate symptoms; limiting instrumental activity of daily living \[ADL\]) or less * STEP 1: Participants must have adequate cardiac function. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2 or better * STEP 1: Participants must not be seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen \[HBsAg\]). Subjects with resolved infection (i.e., subjects who are HBsAg negative but positive for antibodies to hepatitis B core antigen \[anti-HBc\] and/or antibodies to hepatitis B surface antigen \[anti-HBs\]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded. EXCEPTION: Subjects with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR * STEP 1: Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to registration, if indicated * STEP 1: Participants must not have concurrent multiple myeloma as defined by the presence of lytic bone disease, plasmacytomas, \>= 60% plasma cells in the bone marrow, or hypercalcemia. Participants will not be excluded solely based on the presence of plasma cells \> 10% in the bone marrow unless the plasma cell percentage exceeds \>60% * STEP 1: Participants must not have known allergies to any of the study drugs * STEP 1: Participants must not have had a major surgery within 14 days prior to registration and be fully recovered from surgery completed within 14 days prior to registration * STEP 1: Participants must not have a known chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) \< 50% of predicted normal * STEP 1: Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at registration and have undetectable viral load test on the most recent test results obtained within 6 months prior to registration * STEP 1: Participants must not have either moderate or severe persistent asthma within the past 2 years), or currently have uncontrolled asthma of any classification. (Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study) * STEP 1: Participants must not have uncontrolled diabetes within 28 days prior to registration * STEP 1: Participants must not have uncontrolled blood pressure and hypertension within 14 days prior to registration. Participants must have a supine systolic BP of \>= 90 mmHg * STEP 1: Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen * STEP 1: Participants must not have received vaccination with live attenuated vaccines within 28 days prior to Registration to Step 1 * STEP 1: Participants must not have uncontrolled infection at the discretion of the enrolling physician and to be discussed with the study chair if the participant is on active anti-infectious therapy. Any patient on active anti-microbial therapy for chronic infectious issues should be discussed with the study chair prior to enrollment * STEP 1: Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen * STEP 1: Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwestern Oncology group (SWOG) Specimen Tracking System * STEP 1: Participants must agree to have blood, bone marrow core biopsy and aspirate, and fat pad biopsy specimens submitted for minimal residual disease assessment and future exploratory studies * STEP 1: Participants who can complete PRO, QOL, PRO-CTCAE questionnaires, etc. forms in English, Spanish and French must participate in the patient-reported outcomes and quality of life * STEP 2: Participants must have met all eligibility criteria for Step-1 registration * STEP 2: Participants must have achieved at least a partial response * STEP 2: Participants must continue receiving at least one of study drugs (bortezomib, cyclophosphamide, or daratumumab and hyaluronidase-fihj) if another study drug (daratumumab and hyaluronidase-fihj, cyclophosphamide, or bortezomib) has been discontinued due to adverse events. Note: daratumumab and hyaluronidase-fihj cannot be permanently discontinued * STEP 2: Participants must have completed induction therapy * STEP 2: Participants must be registered to Step 2 within 42 days of cycle 3, day 28 of induction therapy * STEP 2: Participants must plan to initiate their assigned consolidation therapy within 8 weeks after randomization * STEP 2: Participants must not have experienced a MOD-PFS event * STEP 2: Participants must have ECOG performance score (PS) of 0, 1, or 2 (PS = 3 may be allowed if secondary to neuropathy) * STEP 2: Participant must have a complete medical history and physical exam within 28 days prior to registration * STEP 2: Participants must be willing to undergo high dose chemotherapy and autologous stem cell transplantation if they are randomized to the arm receiving high dose chemotherapy and autologous stem cell transplantation * STEP 2: Participants randomized to Arm 2 must be willing and able to return to a participating treatment center for their assigned treatment after transplant. Note that participants need not to have a direct relationship with the transplant center in order to register * STEP 2: Participants must be eligible to receive high dose chemotherapy with melphalan at a dose of 200 mg/m\^2 or 140 mg/m\^2 (200 mg/m\^2 is highly encouraged but not mandated). Transplant eligibility criteria are included in the general eligibility criteria listed below: * Patient must have a supine systolic BP \>= 90 mmHg (at registration step-1, this may not by supported by midodrine) * Patient must have non-severe cardiac AL as defined by: * NT proBNP \<5000 (if no NTproBNP, BNP must be available and \< 400 pg/mL) (within 14 days prior to registration step-2) * TnT \< 0.06. If not available, one of the following two criteria must be met (within 14 days prior to registration step-2) * hsTnT \<75 or troponin I \< 0.1ng/dL * NYHA I or II (within 14 days prior to registration step-2) * Cardiac EF \>= 40% (within 14 days prior to registration step-2) * STEP 2: Hemoglobin \> 8.0 g/dL (\> 5 mmol/L); red blood cell transfusion allowed up to 7 days prior to registration (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 2: Leukocytes \>= 2 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 2: Absolute neutrophil count \>= 1.0 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 2: Platelets \>= 50 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 2: Total bilirubin =\< 1.5 times the institutional ULN unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to registration) * STEP 2: Direct bilirubin =\< 2.0 mg/dL (except if secondary to hepatic involvement) (within 28 days prior to registration) * STEP 2: AST/ALT =\< 3x upper limit of normal (ULN) (except if secondary to hepatic involvement) (within 28 days prior to registration) * STEP 2: Alkaline phosphatase =\< 750 U/L (except if secondary to hepatic involvement) (within 28 days prior to registration) * STEP 2: Participants must have a serum creatinine =\< the IULN OR calculated creatinine clearance ≥ 30 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration * STEP 2: Participants must not have uncontrolled infection at the discretion of the enrolling physician and to be discussed with the study chair if the participant is on active anti-infectious therapy. Any patient on active anti-microbial therapy for chronic infectious issues should be discussed with the study chair prior to enrollment * STEP 2: Participants randomized to the ASCT arm must be able to have at least 2.0 x 10\^6 CD34 cells/kg collected * STEP 2: Participants who can complete PRO, QOL, PRO-CTCAE questionnaires, etc. forms in English, Spanish and French must participate in the patient-reported outcomes and quality of life * STEP 3: Participants must have met all eligibility criteria for Step-1 and Step-2 registration * STEP 3: Participants must not have had daratumumab and hyaluronidase-fihj permanently discontinued during induction or consolidation * STEP 3: Participants must have completed induction and consolidation therapy * STEP 3: Participants must be registered to Step 3 within the following time frames: * If randomized to Arm 1 Dara-VCD consolidation: within 28 days of completion of 3 cycles of consolidation therapy * If randomized to Arm 2 high dose chemotherapy and autologous stem cell transplantation: within 180 days following initiation of stem cell transplantation * STEP 3: Participants must not have experienced a MOD-PFS event * STEP 3: Participants must have ECOG performance score (PS) of 0, 1, or 2 (PS = 3 is allowed if secondary to neuropathy) * STEP 3: Participants must have a complete medical history and physical exam within 28 DAYS prior to registration * STEP 3: Hemoglobin \> 8.0 g/dL (\> 5 mmol/L); red blood cell transfusion allowed up to 7 days prior to registration (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 3: Leukocytes \>= 2 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 3: Absolute neutrophil count \>= 1.0 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 3: Platelets \>= 50 x 10\^3/uL (within 28 days prior to registration) (NOTE: Growth factor support \[G-CSF\] is permitted per institutional guidelines) * STEP 3: Total bilirubin =\< 1.5 times the institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional ULN (within 28 days prior to registration) * STEP 3: Direct bilirubin =\< 2.0 mg/dL (within 28 days prior to registration) * STEP 3: AST/ALT =\< 3x upper limit of normal (ULN) (except if secondary to hepatic involvement) (within 28 days prior to registration) * STEP 3: Alkaline phosphatase =\< 750 U/L (except if secondary to hepatic involvement) (within 28 days prior to registration) * STEP 3: Participants must not have uncontrolled infection at the discretion of the enrolling physician and to be discussed with the study chair if the participant is on active anti-infectious therapy. Any patient on active anti-microbial therapy for chronic infectious issues should be discussed with the study chair prior to enrollment * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AL amyloidosis Immunoglobulin Light-chain Amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Al amyloidosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

The study's own enquiry address

This study publishes an address for enquiries. See it below .
The places running it

116 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Show contact details

Locations

Abbott-Northwestern Hospital
RECRUITING

Minneapolis, Minnesota, 55407, United States
Allegiance Health
RECRUITING

Jackson, Michigan, 49201, United States

Contact Email: •••••@•••••
Banner University Medical Center - Tucson
RECRUITING

Tucson, Arizona, 85719, United States
Baptist Memorial Hospital and Cancer Center-Collierville
RECRUITING

Collierville, Tennessee, 38017, United States

Contact Email: •••••@•••••
Baptist Memorial Hospital and Cancer Center-Desoto
RECRUITING

Southhaven, Mississippi, 38671, United States

Contact Email: •••••@•••••
Baptist Memorial Hospital and Cancer Center-Memphis
RECRUITING

Memphis, Tennessee, 38120, United States

Contact Email: •••••@•••••
Baptist Memorial Hospital and Cancer Center-Oxford
RECRUITING

Oxford, Mississippi, 38655, United States

Contact Email: •••••@•••••
Boston Medical Center
RECRUITING

Boston, Massachusetts, 02118, United States
CTCA at Western Regional Medical Center
RECRUITING

Goodyear, Arizona, 85338, United States
Carle Cancer Center
RECRUITING

Urbana, Illinois, 61801, United States

Contact Email: •••••@•••••
Carle Physician Group-Effingham
RECRUITING

Effingham, Illinois, 62401, United States

Contact Email: •••••@•••••
Carle Physician Group-Mattoon/Charleston
RECRUITING

Mattoon, Illinois, 61938, United States

Contact Email: •••••@•••••
Carle at The Riverfront
RECRUITING

Danville, Illinois, 61832, United States

Contact Email: •••••@•••••
Case Western Reserve University
RECRUITING

Cleveland, Ohio, 44106, United States

Contact Email: •••••@•••••
City of Hope Comprehensive Cancer Center
RECRUITING

Duarte, California, 91010, United States

Contact Email: •••••@•••••
City of Hope at Irvine Lennar
RECRUITING

Irvine, California, 92618, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
Fairview Southdale Hospital
RECRUITING

Edina, Minnesota, 55435, United States
Geisinger Medical Center
RECRUITING

Danville, Pennsylvania, 17822, United States

Contact Email: •••••@•••••
Geisinger Wyoming Valley/Henry Cancer Center
RECRUITING

Wilkes-Barre, Pennsylvania, 18711, United States

Contact Email: •••••@•••••
Gundersen Lutheran Medical Center
RECRUITING

La Crosse, Wisconsin, 54601, United States

Contact Email: •••••@•••••
Henry Ford Cancer Institute-Downriver
RECRUITING

Brownstown, Michigan, 48183, United States

Contact Email: •••••@•••••
Henry Ford Hospital
RECRUITING

Detroit, Michigan, 48202, United States

Contact Email: •••••@•••••
Henry Ford Macomb Hospital-Clinton Township
RECRUITING

Clinton Township, Michigan, 48038, United States

Contact Email: •••••@•••••
Henry Ford Medical Center-Columbus
RECRUITING

Novi, Michigan, 48377, United States

Contact Email: •••••@•••••
Henry Ford Medical Center-Fairlane
RECRUITING

Dearborn, Michigan, 48126, United States

Contact Email: •••••@•••••
Henry Ford West Bloomfield Hospital
RECRUITING

West Bloomfield, Michigan, 48322, United States

Contact Email: •••••@•••••
Henry Ford Wyandotte Hospital
RECRUITING

Wyandotte, Michigan, 48192, United States
Houston Methodist Cypress Hospital
RECRUITING

Cypress, Texas, 77429, United States
Houston Methodist Hospital
RECRUITING

Houston, Texas, 77030, United States
Houston Methodist Saint John Hospital
RECRUITING

Nassau Bay, Texas, 77058, United States
Houston Methodist San Jacinto Hospital
RECRUITING

Baytown, Texas, 77521, United States
Houston Methodist Sugar Land Hospital
RECRUITING

Sugar Land, Texas, 77479, United States
Houston Methodist The Woodlands Hospital
RECRUITING

The Woodlands, Texas, 77385, United States
Houston Methodist West Hospital
RECRUITING

Houston, Texas, 77094, United States
Iowa Methodist Medical Center
RECRUITING

Des Moines, Iowa, 50309, United States
Karmanos Cancer Institute at McLaren Greater Lansing
RECRUITING

Lansing, Michigan, 48910, United States

Contact Email: •••••@•••••
Loyola University Medical Center
RECRUITING

Maywood, Illinois, 60153, United States
M D Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States
MedStar Georgetown University Hospital
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering Bergen
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Commack
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Westchester
RECRUITING

Harrison, New York, 10604, United States
Mercy Hospital
RECRUITING

Coon Rapids, Minnesota, 55433, United States
Methodist Willowbrook Hospital
RECRUITING

Houston, Texas, 77070, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
RECRUITING

New York, New York, 10032, United States

Contact Email: •••••@•••••
Nebraska Medicine-Bellevue
RECRUITING

Bellevue, Nebraska, 68123, United States
Nebraska Medicine-Village Pointe
RECRUITING

Omaha, Nebraska, 68118, United States
Novant Health Cancer Institute - Huntersville
RECRUITING

Huntersville, North Carolina, 28078, United States
Novant Health Cancer Institute - Mooresville
RECRUITING

Mooresville, North Carolina, 28117, United States
Novant Health Forsyth Medical Center
RECRUITING

Winston-Salem, North Carolina, 27103, United States
Novant Health Presbyterian Medical Center
RECRUITING

Charlotte, North Carolina, 28204, United States
Oregon Health and Science University
ACTIVE_NOT_RECRUITING

Portland, Oregon, 97239, United States
Park Nicollet Clinic - Saint Louis Park
RECRUITING

Saint Louis Park, Minnesota, 55416, United States
Providence Newberg Medical Center
RECRUITING

Newberg, Oregon, 97132, United States

Contact Email: •••••@•••••
Providence Portland Medical Center
RECRUITING

Portland, Oregon, 97213, United States

Contact Email: •••••@•••••
Providence Saint Vincent Medical Center
RECRUITING

Portland, Oregon, 97225, United States

Contact Email: •••••@•••••
Providence Willamette Falls Medical Center
RECRUITING

Oregon City, Oregon, 97045, United States

Contact Email: •••••@•••••
Regions Hospital
RECRUITING

Saint Paul, Minnesota, 55101, United States
Riverside Methodist Hospital
RECRUITING

Columbus, Ohio, 43214, United States
Rush-Copley Medical Center
RECRUITING

Aurora, Illinois, 60504, United States
Saint Vincent Hospital Cancer Center Green Bay
RECRUITING

Green Bay, Wisconsin, 54301, United States
Saint Vincent Hospital Cancer Center at Oconto Falls
RECRUITING

Oconto Falls, Wisconsin, 54154, United States
Saint Vincent Hospital Cancer Center at Saint Mary's
RECRUITING

Green Bay, Wisconsin, 54303, United States
Saint Vincent Hospital Cancer Center at Sheboygan
RECRUITING

Sheboygan, Wisconsin, 53081, United States
Saint Vincent Hospital Cancer Center at Sturgeon Bay
RECRUITING

Sturgeon Bay, Wisconsin, 54235-1495, United States
Sheboygan Physicians Group
RECRUITING

Sheboygan, Wisconsin, 53081, United States
Siteman Cancer Center at Christian Hospital
RECRUITING

St Louis, Missouri, 63136, United States

Contact Email: •••••@•••••
Siteman Cancer Center at Saint Peters Hospital
RECRUITING

City of Saint Peters, Missouri, 63376, United States

Contact Email: •••••@•••••
Siteman Cancer Center at West County Hospital
RECRUITING

Creve Coeur, Missouri, 63141, United States

Contact Email: •••••@•••••
Siteman Cancer Center-South County
RECRUITING

St Louis, Missouri, 63129, United States

Contact Email: •••••@•••••
Smilow Cancer Hospital Care Center - Guilford
RECRUITING

Guilford, Connecticut, 06437, United States

Contact Email: •••••@•••••
Smilow Cancer Hospital Care Center at Greenwich
RECRUITING

Greenwich, Connecticut, 06830, United States

Contact Email: •••••@•••••
Smilow Cancer Hospital Care Center at Long Ridge
RECRUITING

Stamford, Connecticut, 06902, United States

Contact Email: •••••@•••••
Smilow Cancer Hospital Care Center at Saint Francis
RECRUITING

Hartford, Connecticut, 06105, United States

Contact Email: •••••@•••••
Smilow Cancer Hospital Care Center-Trumbull
RECRUITING

Trumbull, Connecticut, 06611, United States

Contact Email: •••••@•••••
Smilow Cancer Hospital-Derby Care Center
RECRUITING

Derby, Connecticut, 06418, United States

Contact Email: •••••@•••••
Thomas Jefferson University Hospital
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

Contact Email: •••••@•••••
UC Irvine Health/Chao Family Comprehensive Cancer Center
RECRUITING

Orange, California, 92868, United States

Contact Email: •••••@•••••
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
RECRUITING

Irvine, California, 92612, United States

Contact Email: •••••@•••••
UI Health Care Mission Cancer and Blood - Ankeny Clinic
RECRUITING

Ankeny, Iowa, 50023, United States
UI Health Care Mission Cancer and Blood - Des Moines Clinic
RECRUITING

Des Moines, Iowa, 50309, United States
UI Health Care Mission Cancer and Blood - Laurel Clinic
RECRUITING

Des Moines, Iowa, 50314, United States
UI Health Care Mission Cancer and Blood - Waukee Clinic
RECRUITING

Waukee, Iowa, 50263, United States
UI Health Care Mission Cancer and Blood - West Des Moines Clinic
RECRUITING

Clive, Iowa, 50325, United States
UM Sylvester Comprehensive Cancer Center at Aventura
RECRUITING

Aventura, Florida, 33180, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
RECRUITING

Coral Gables, Florida, 33146, United States
UM Sylvester Comprehensive Cancer Center at Coral Springs
RECRUITING

Coral Springs, Florida, 33065, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
RECRUITING

Deerfield Beach, Florida, 33442, United States
UM Sylvester Comprehensive Cancer Center at Hollywood
RECRUITING

Hollywood, Florida, 33021, United States
UM Sylvester Comprehensive Cancer Center at Kendall
RECRUITING

Miami, Florida, 33176, United States
UM Sylvester Comprehensive Cancer Center at Plantation
RECRUITING

Plantation, Florida, 33324, United States
United Hospital
RECRUITING

Saint Paul, Minnesota, 55102, United States
University of Arizona Cancer Center-North Campus
RECRUITING

Tucson, Arizona, 85719, United States
University of Illinois
RECRUITING

Chicago, Illinois, 60612, United States
University of Kansas Cancer Center
RECRUITING

Kansas City, Kansas, 66160, United States
University of Kansas Hospital-Westwood Cancer Center
RECRUITING

Westwood, Kansas, 66205, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
RECRUITING

Miami, Florida, 33136, United States
University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
RECRUITING

North Miami, Florida, 33181, United States
University of Michigan Rogel Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact Email: •••••@•••••
University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States
University of Pennsylvania/Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Email: •••••@•••••
University of Rochester
RECRUITING

Rochester, New York, 14642, United States
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
RECRUITING

Madison, Wisconsin, 53718, United States

Contact Email: •••••@•••••
University of Wisconsin Carbone Cancer Center - University Hospital
RECRUITING

Madison, Wisconsin, 53792, United States

Contact Email: •••••@•••••
Walter Reed National Military Medical Center
RECRUITING

Bethesda, Maryland, 20889-5600, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

Contact Email: •••••@•••••
Wayne State University/Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States

Contact Email: •••••@•••••
Weisberg Cancer Treatment Center
RECRUITING

Farmington Hills, Michigan, 48334, United States

Contact Email: •••••@•••••
Yale University
RECRUITING

New Haven, Connecticut, 06520, United States

Contact Email: •••••@•••••
Yale-New Haven Hospital North Haven Medical Center
RECRUITING

North Haven, Connecticut, 06473, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.